Precision cancer biotech Abion Inc. announced a positive interim phase II readout for ABN-401, its novel c-mesenchymal-epithelial transition (c-MET)-targeting tyrosine kinase inhibitor (TKI) for advanced non-small-cell lung cancer (NSCLC), lighting a runway to its next trial as a combination regimen.
Precision cancer biotech Abion Inc. announced a positive interim phase II readout for ABN-401, its novel c-mesenchymal-epithelial transition (c-MET)-targeting tyrosine kinase inhibitor (TKI) for advanced non-small-cell lung cancer (NSCLC), lighting a runway to its next trial as a combination regimen.
Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with documented efficacy in non-small-cell lung cancer. However, in most cases, patients develop resistance to this treatment by mechanisms that are not clear in half of the cases. Researchers from Shanghai Pulmonary Hospital presented data on BC-3448, a bispecific antibody targeting EGFR and CD3 aimed to recruit T cells to tumors with high EGFR expression leading to T cell-driven tumor cell killing. The compound presents a stronger binding affinity for EGFR than for CD3 to avoid the development of cytokine release syndrome, which is a safety issue common in CD3-based bispecific antibodies.
Biocity Biopharma announced that the U.S. FDA has accepted its investigational new drug (IND) application for BC-3448, a bispecific antibody that targets the T cell marker CD3 and epidermal growth factor receptor (EGFR), bringing antitumor T cells in proximity to EGFR-expressing cells. To reduce the risk of cytokine release syndrome (CRS), a known risk of CD3-targeting antibodies, the bispecific has a higher affinity for EGFR than CD3.
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. presented the discovery and preclinical evaluation of novel EGFR(T790M/C797S) inhibitors for the treatment of mutant non-small-cell lung cancer (NSCLC).
The dose-escalation portion of Black Diamond Therapeutics Inc.’s phase I study of BDTX-1535 for treating non-small-cell lung cancer (NSCLC) produced strong data that moved the market in a big way.
CSPC Pharmaceutical Group Ltd. has received FDA clearance of its IND for a phase I trial of its antibody-drug conjugate CPO-301 for the treatment of advanced lung cancer with alterations in the EGFR gene or EGFR over-expression.
Deka Biosciences Inc.'s IND application has been cleared by the FDA allowing the company to proceed with a phase I trial of DK-210 (EGFR) in patients with advanced solid cancer overexpressing epidermal growth factor receptors (EGFR).
Aethon Therapeutics Inc. closed a $30 million series A round to develop a novel antibody-based therapeutic strategy for cancer, which relies on the concomitant use of small-molecule covalent inhibitors that form peptide-drug conjugates or beacons.
